Meerut Reporter

Influenza A Market to Observe Growth at a CAGR of 8.5% in the United States for the Study Period (2019-2032), Estimates DelveInsight

 Breaking News
  • No posts were found

Influenza A Market to Observe Growth at a CAGR of 8.5% in the United States for the Study Period (2019-2032), Estimates DelveInsight

January 19
20:41 2023
Influenza A Market to Observe Growth at a CAGR of 8.5% in the United States for the Study Period (2019-2032), Estimates DelveInsight
Influenza A Market

DelveInsight’s Influenza A Market Insights report includes a comprehensive understanding of current treatment practices, influenza A emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

 

Key Takeaways from the Influenza A Market Report

  • As per DelveInsight analysis, the influenza A market size in the US was approximately USD 3.6 billion in 2021
  • According to the assessment done by DelveInsight, the total vaccinated pool of influenza A in the United States was approximately 176 million in 2021
  • Leading influenza A companies such as Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, Genentech, Roche, BioCryst Pharmaceuticals, Sanofi, AstraZeneca, Seqirus, GSK, and others are developing novel influenza A drugs that can be available in the influenza A market in the coming years
  • The promising influenza A therapies/vaccines in the pipeline include CD388, SAB-176, M2SR, VIR-2482, mRNA-1010, GSK3206641A, VXA-A1.1, and others
  • The increase in influenza A market size is a direct consequence of an increase in R&D activity, the increasing prevalent population, and the expected commercial success of upcoming therapies.
  • In September 2022Cidara Therapeutics announced the initiation of its Phase IIa trial to evaluate the pre-exposure prophylactic activity of CD388 against the influenza virus
  • In April 2021, Cidara Therapeutics announced that they have entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, to develop and commercialize Cidara’s Cloudbreak drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza

 

Discover which therapies are expected to grab the major influenza A market share @ Influenza A Market Report

 

Influenza A Overview

Influenza is an acute viral respiratory disease caused by respiratory tract infection with influenza viruses (seasonal influenza A and B viruses) that circulate worldwide. Unlike annual seasonal epidemics, sporadic pandemic outbreaks are caused by zoonotic influenza A virus strains.

Symptoms of influenza virus infection range from mild upper respiratory disease characterized by fever, sore throat, runny nose, cough, headache, muscle pain, and fatigue to severe and, in some cases, lethal pneumonia caused by influenza virus or secondary bacterial infection of the lower respiratory tract.

The clinical presentation and epidemiological likelihood of infection are used to make an influenza A diagnosis. Nonspecific influenza A symptoms, such as fever, chills, frank shaking, headaches, myalgia, malaise, and anorexia, predominate at first. These influenza A symptoms usually appear suddenly, and respiratory symptoms, such as a dry cough, sore or dry throat, nasal obstruction, and discharge, are also present.

 

Influenza A Epidemiology Segmentation

DelveInsight estimates that total influenza A positive cases in the United States comprised approximately 42.5K cases in 2021 and are projected to increase during the study period.

In the United States, there were (H1N1)pdm09, H3N2, and subtyping not performed 19, 7,405, and 35,156 cases in 2021.

 

The influenza A market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Vaccinated Pool of Influenza A
  • Influenza A Positive Cases
  • Strain-specific Cases of Influenza A (2019–2022)

 

Download the report to understand which factors are driving influenza A epidemiology trends @ Influenza A Epidemiological Insights

 

Influenza A Treatment Market 

Early antiviral intervention can benefit public health by improving clinical outcomes for patients at high risk of influenza-related complications, as well as potentially saving patients and the healthcare system money. MedImmune introduced the first licensed live attenuated influenza virus vaccine (LAIV) in the United States in 2003. This vaccine is based on the influenza A/Ann Arbor/6/1960 backbones. LAIVs appear to be more effective than inactivated influenza virus preparations at inducing mucosal and broadly protective immune responses in infants and children. However, studies in the United States with LAIVs have revealed poor efficacy against influenza A H1N1 component1.

Another breakthrough for influenza vaccines occurred in 2013 when the FDA approved FLUZONE QUADRIVALENT, a product made entirely of recombinant DNA technologies. Antiviral drugs, in conjunction with vaccines, are critical in preventing and treating influenza virus infection and disease. During a typical influenza season, antiviral drugs are primarily used to treat severely ill patients, particularly those with a compromised immune system. TAMIFLU, RELENZA, and RAPIVAB are approved therapies that work by mimicking sialic acid binding in the active site of NA on influenza A and B viruses.

 

To know more about influenza A guidelines, visit @ Influenza A Treatment Options

 

Influenza A Pipeline Therapies/Vaccines and Key Companies

  • CD388: Cidara Therapeutics
  • SAB-176: SAb Biotherapeutics
  • M2SR: FluGen
  • mRNA-1010: Moderna
  • VIR-2482: Vir Biotechnology
  • VXA-A1.1: Vaxart

 

Learn more about the FDA-approved influenza A drugs @ Drugs for Influenza A Treatment 

 

Influenza A Market Dynamics

The dynamics of the influenza A market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. Moreover, the presence of a large number of manufacturers contributes to the influenza A market growth. Furthermore, key players are heavily investing in research activities to broaden the therapeutic application of treatment drugs, thereby expanding the scope and opportunities for the treatment, thereby boosting the influenza A market growth.

However, certain factors act as barriers and affect the influenza A market growth. The inadequate epidemiological data availability of patient care reference centers is among the prominent factors hampering the growth of the influenza A market. Moreover, the global influenza A market is fragmented, owing to the presence of several major players. Furthermore, payers and insurance companies will attempt to limit the use of drugs with mediocre efficacy but high prices, thus leading to a dip in the growth of the influenza A market. Hence, all these factors mentioned above are likely to impede the influenza A market growth in the future.

 

Scope of the Influenza A Market Report

  • Therapeutic Assessment: Influenza A current marketed and emerging therapies
  • Influenza A Market Dynamics: Influenza A market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Influenza A Market Access and Reimbursement

 

Discover more about influenza A drugs in development @ Influenza A Clinical Trials

 

Table of Contents

1.

Influenza A Market Key Insights

2.

Influenza A Market Report Introduction

3.

Influenza A Market Executive Summary

4.

Influenza A Key Events

5.

Epidemiology and Market Methodology

6.

Influenza A Market Overview at a Glance

7.

Influenza A Disease Background and Overview

8.

Influenza A Treatment and Management

9.

Influenza A Epidemiology and Patient Population in the 7MM

9.1

Key Findings

9.2

Assumptions and Rationale

9.3

Total Vaccinated Pool of Influenza A in the 7MM

9.4

United States

9.5

EU-4 and the UK

9.6

Japan

10

Patient Journey

11

Key Endpoints in Influenza A

12

Influenza A Marketed Vaccines and Drugs

13

Influenza A Emerging Vaccines and Drugs

13.1

Seven Major Influenza A Market Analysis

13.2

Key Findings

13.3

Market Outlook

13.4

Key Market Forecast Assumptions

13.5

Total Market size of Influenza A in the 7MM

13.6

United States Market Size

13.7

EU-4 and the UK Market Size

13.8

Japan Market Size

14

Market Access And Reimbursement

15

SWOT Analysis

16

Unmet Needs

17

Appendix

18

DelveInsight Capabilities

19

Disclaimer

20

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting